Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Type 1 diabetes arises from a failure of insulin secretion, which leads to elevated blood glucose and disturbances in carbohydrate, fat and protein metabolism. There is no means of either preventing or curing type 1 diabetes. Instead, life-long insulin replacement and monitoring of blood glucose levels are required. The conventional means for taking insulin has for some time involved several injections each day, usually two, three or four. However, continuous subcutaneous insulin infusion provides an alternative. Our Cochrane review compares multiple injections with continuous subcutaneous insulin infusion (1). Continuous subcutaneous insulin infusion, or CSII, involves attachment, via a catheter, to an insulin pump. The pump is programmed to deliver insulin to match the person's needs. They can also deliver extra doses themselves to cover meals and correct blood glucose fluctuations. Before starting the review, we knew of numerous studies that had evaluated the two ways of administering insulin but many of these were of poor quality and previous reviews were either out of date or had not used rigorous methodology. This meant that there was uncertainty about which treatment is better. To overcome this, we used a carefully prespecified methodology and searched the literature up to July of 2009. We found and reviewed 23 studies, published from 1982 to 2008. These had recruited a total of 976 patients from a dozen different countries across Europe, North America and the Middle East. Most of the studies had been done in adults, but seven were performed in children. Compared to multiple injections, CSII led to a slight improvement in overall blood glucose control and reduced the frequency of severe hypoglycaemia by at least 50% in most studies. We were not able to investigate short and long term adverse effects, and late complications of diabetes or mortality, because of a lack of data in the trials. While our Cochrane review presents a rigorous and comprehensive analysis of the evidence, there are still many issues that need to be addressed in future trials. Type 1 diabetes may occur at any age and it is one of the most common chronic diseases of childhood and adolescence, so it is interesting that so few patients took part in these trials comparing CSII with multiple injections. Although there is a relatively large number of studies, 23, these tended to be fairly small. The largest recruited 275 patients, but eighteen of the studies had fewer than 50 participants. It is important to be cautious about conclusions drawn from such small trials. Evidence about adverse effects, late complications and mortality is also essential to well informed decision making and needs to be gathered in large scale methodologically rigorous trials. Information about cost effectiveness would also help in making the choice between these two types of insulin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Misso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406
Self-citation
Cited by
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Chiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 509
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Metadata
- Authors
- Misso, M. L.
- Venue
- Journal of Evidence-Based Medicine
- Publisher
- Wiley
- Published
- 2010-08
- Volume
- 3
- Issue
- 3
- Pages
- 186-186
- ISSN
- 1756-5383 (ISSN-L)
- 1756-5391
- OpenAlex
- W4241267177
- Cited by
- 113
- References
- 1
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. https://app.cochat.ai/papers/10.1111/j.1756-5391.2010.01094.x
- The paper
- Misso, M. L. (2010). Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Journal of Evidence-Based Medicine. https://doi.org/10.1111/j.1756-5391.2010.01094.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.